dc.creatorSAENZ, R.
dc.creatorSOUZA, C. da Silva
dc.creatorHUANG, C. -T.
dc.creatorLARSSON, M.
dc.creatorESENER, S.
dc.creatorMESSMER, D.
dc.date.accessioned2012-10-19T22:49:52Z
dc.date.accessioned2018-07-04T15:16:11Z
dc.date.available2012-10-19T22:49:52Z
dc.date.available2018-07-04T15:16:11Z
dc.date.created2012-10-19T22:49:52Z
dc.date.issued2010
dc.identifierVACCINE, v.28, n.47, p.7556-7562, 2010
dc.identifier0264-410X
dc.identifierhttp://producao.usp.br/handle/BDPI/24114
dc.identifier10.1016/j.vaccine.2010.08.054
dc.identifierhttp://dx.doi.org/10.1016/j.vaccine.2010.08.054
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1620842
dc.description.abstractThere is a need for new adjuvants that will induce immune responses to subunit vaccines. We show that a short peptide, named Hp91, whose sequence corresponds to an area within the endogenous molecule high mobility group box (HMGB1) protein 1 potentiates cellular immune responses to peptide antigen and cellular and humoral immune responses to protein antigen in vivo. Hp91 promoted the in vivo production of the immunomodulatory cytokines, IFN-gamma, TNF-alpha, IL-6, and IL-12 (p70), as well as antigen-specific activation of CD8+ T cells. These results demonstrate the ability of a short immunostimulatory peptide to serve as an adjuvant for subunit vaccines. (C) 2010 Elsevier Ltd. All rights reserved.
dc.languageeng
dc.publisherELSEVIER SCI LTD
dc.relationVaccine
dc.rightsCopyright ELSEVIER SCI LTD
dc.rightsrestrictedAccess
dc.subjectHMGB-1 peptides
dc.subjectAdjuvants
dc.subjectVaccine
dc.subjectImmunotherapy
dc.subjectDendritic cells
dc.titleHMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución